Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $34.6 million.

  • Angiodynamics' Cost of Revenue rose 519.45% to $34.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $139.6 million, marking a year-over-year increase of 302.53%. This contributed to the annual value of $134.8 million for FY2025, which is 966.59% down from last year.
  • Per Angiodynamics' latest filing, its Cost of Revenue stood at $34.6 million for Q4 2025, which was up 519.45% from $33.9 million recorded in Q3 2025.
  • Angiodynamics' 5-year Cost of Revenue high stood at $44.7 million for Q2 2023, and its period low was $30.8 million during Q3 2024.
  • Its 5-year average for Cost of Revenue is $36.7 million, with a median of $37.3 million in 2021.
  • In the last 5 years, Angiodynamics' Cost of Revenue surged by 2276.67% in 2021 and then plummeted by 2739.57% in 2024.
  • Angiodynamics' Cost of Revenue (Quarter) stood at $37.7 million in 2021, then grew by 6.96% to $40.4 million in 2022, then decreased by 3.82% to $38.8 million in 2023, then fell by 15.13% to $32.9 million in 2024, then increased by 5.19% to $34.6 million in 2025.
  • Its Cost of Revenue was $34.6 million in Q4 2025, compared to $33.9 million in Q3 2025 and $37.9 million in Q2 2025.